Heilongjiang ZBD Pharmaceutical Co Ltd

603567.CG▼

Zhenbaodao's 2026 interim report shows net loss of 271 million yuan, widening year-on-year

Zhenbaodao released its 2026 interim report. During the reporting period, the company's total operating revenue was 296 million yuan, down 58.60% year-on-year. Net profit attributable to the parent company was negative 271 million yuan, a decrease of 193 million yuan compared with the same period last year, with the loss widening. Net cash inflow from operating activities was 103 million yuan. The asset-liability ratio was 41.08%, gross margin was 5.53%, ROE was negative 4.51%, and diluted earnings per share was negative 0.29 yuan. The number of shareholders was 31,000, and the top ten shareholders held 62.54% of total share capital.

Heilongjiang Z… ▼

603567.CG · Capital · Negative Net loss widened to 271 million yuan with revenue down 58.6%.

Read original ↗

Jiemian·34dRead more →

China

603567.CG▼

Zhenbaodao's first-half loss widens to 271 million yuan

Zhenbaodao released its 2026 interim report, showing first-half operating revenue of 295 million yuan, down 58.6% year on year, while net profit attributable to the parent swung from a loss of 78.29 million yuan in the same period last year to a loss of 271 million yuan. Second-quarter revenue was 114 million yuan, down 53.5% year on year, and the net loss attributable to the parent was 91.03 million yuan, narrowing from a loss of 154 million yuan a year earlier. As of the end of the second quarter, the company's total assets stood at 10.268 billion yuan, down 3.4% from the end of the previous year, and net assets attributable to the parent were 6.011 billion yuan, down 4.3%. The company said that, affected by pharmaceutical sales falling short of expectations, there is a risk of continued decline in revenue and profit, and it is responding by participating in centralized procurement and increasing research and development investment.

Heilongjiang Z… ▼

603567.CG · Capital · Negative First-half net loss widened to 271 million yuan from 78.29 million yuan loss a year earlier, with revenue down 58.6%.

Read original ↗

财中社·37dRead more →

603567.CG▲

Traditional Chinese Medicine Stocks Surge Against the Market as Pien Tze Huang and ZBD Pharma Hit Limit Up, While Chip Stocks Plunge Across the Board

China's A-share market underwent volatile adjustments today, with the Shanghai Composite Index falling 1.85 percent and losing the 3,900-point level. However, the traditional Chinese medicine sector surged against the market, with Pien Tze Huang and ZBD Pharma hitting their daily limit up in the afternoon. The pharmaceutical and biological industry saw a net inflow of over 5 billion yuan in main funds, and the TCM sector index rose more than 3 percent at one point during the session, marking seven consecutive positive daily candlesticks. Harbin Pharmaceutical Group locked in its fifth straight daily limit up, while Hainan Haiyao achieved its second consecutive daily limit up. Chip stocks, on the other hand, suffered a broad sell-off, with the semiconductor sector index plunging more than 5 percent. Companies such as JCET and Demingli hit limit down in batches. Global chip stocks also faced heavy selling, with South Korea's SK Hynix tumbling 11.53 percent and Japan's Kioxia plummeting 15.03 percent. On the news front, the State Council approved the 15th Five-Year Plan for the Revitalization and Development of Traditional Chinese Medicine, and the 2026 edition of the National Essential Medicines List added 48 new proprietary Chinese medicines.

Zhangzhou Pien… ▲Heilongjiang Z… ▲SK Hynix Inc ▼285A.JP ▼JCET Group Co… ▼Hainan Haiyao… ▲+2

600436.CG · Regulation · Positive State Council approved 15th Five-Year Plan for TCM revitalization, boosting sector sentiment.

603567.CG · Regulation · Positive ZBD Pharma hit limit up as TCM stocks rallied on State Council plan and essential medicines list expansion.

000660.KO · Demand · Negative SK Hynix tumbled 11.53% as global chip stocks faced heavy selling.

285A.JP · Demand · Negative Kioxia plummeted 15.03% amid global chip stock sell-off.

600584.CG · Demand · Negative Chip stocks plunged across the board amid broad sell-off; JCET hit limit down.

000566.CS · Regulation · Positive Hainan Haiyao achieved second consecutive limit up amid TCM sector surge driven by policy news.

Read original ↗

证券时报·80dRead more →